Last reviewed · How we verify
NCT05988177
Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
NA trial testing Carrimycin tablets in Carbapenem Resistant Bacterial Infection in 20 participants. Not yet recruiting.
30 August 2026
Quick facts
| Lead sponsor | Beijing Friendship Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 30 August 2023 |
| Primary completion | 30 August 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Carrimycin tablets — full drug profile →
Conditions studied
- Carbapenem Resistant Bacterial Infection — all drugs for Carbapenem Resistant Bacterial Infection →
- Hemophagocytic Lymphohistiocytoses — all drugs for Hemophagocytic Lymphohistiocytoses →
Sponsor
Beijing Friendship Hospital
Who can join
18 and older, any sex, with Carbapenem Resistant Bacterial Infection or Hemophagocytic Lymphohistiocytoses. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05988177
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Carbapenem Resistant Bacterial Infection
Currently open trials in the same condition.
- NCT07004049 — Optimising TREATment for Severe Gram-Negative Bacterial Infections · Phase 4 · recruiting
- NCT07226557 — Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: · active not recruiting
- NCT06392568 — Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units · recruiting
Other Beijing Friendship Hospital trials
Trials by the same sponsor.
- NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
- NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
- NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
- NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05988177 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
- Last refreshed: 14 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05988177.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing